Published: 10 Jan, 2019 |Tags: iCertainty, Approval, Blood Flow Clearance, FDA, 510(k),
Receives, RFPi, Surgeries
Published: 10 Jan, 2019 |Tags: Rafael Pharmaceuticals, (AML), (CPI-613), (mPC),
Devimistat, EMA, Metastatic, Pancreatic Cancer, ODD, R/R, Acute, Myeloid
Leukemia, Receives
Published:10 Jan, 2019 |Tags: Agreement, Exclusive, Glenmark, License, Ryaltris, Signs,
Yuhan
Published: 10 Jan, 2019 |Tags: (lurasidone), JEWEL Study, Lurasidone, Hydrochloride,
P-III, Reports, Results, Schizophrenia, Sumitomo, Dainippon
5. Empatica’s Embrace an AI Smartwatch Receives FDA’s 510(K) Clearance Approval in Pediatric
Patients Aged ≥6 yrs.
Published: 09 Jan, 2019 |Tags: Embrace, Empatica, FDA’s, 510(K), Pediatric, Receives,
Smartwatch, Aged, AI Approval, Clearance
6. ONO Pharmaceutical Reports Results of Opdivo (nivolumab) in P-III ATTRACTION-3
Study in Patients with Unresectable or Recurrent Esophageal Cancer
Published: 09 Jan, 2019 |Tags: ATTRACTION-3, Esophageal Cancer, ONO Pharmaceutical,
Opdivo, P-III, Recurrent, Reports, Results, Unresectable
Published: 09 Jan, 2019 |Tags: Collabortaes, Develop, Elevian, Insilico, Medicine,
Therapies, Targeting, Aging
8. Sanofi Reports Results of Cablivi (caplacizumab) in P-III HERCULES study in Patients
with Rare Blood Clotting Disorder, Published in NEJM
Published: 09 Jan, 2019 |Tags: (caplacizumab), Cablivi, HERCULES study, NEJM, P-III,
Published, Rare Blood, Clotting, Disorder, Reduction, Reports, Results, Sanofi
Published: 07 Jan, 2019 |Tags: J&J, Janssen, Reports, Stelara, UC, Ulcerative Colitis,
Variation, (ustekinumab) Application, EMA, Moderately to Severely, Active,
Filing, Group, Type II
10. ImmunoGen to Sell Residual Royalty Rights for Kadcyla (ado-trastuzumab emtansine) to
OMERS
Published: 08 Jan, 2019 |Tags: ImmunoGen, (ado-trastuzumab emtansine), Kadcyla, OMERS,
ImmunoGen, Residual, Rights, Royalty Sell
11. Exelixis and Daiichi Sankyo’s Minnebro (Esaxerenone) Receives MHLW Marketing Approval in
Patients with Hypertension in Japan
Published: 08 Jan, 2019 |Tags: Daiichi Sankyo, Exelixis, Hypertension, (Esaxerenone),
Japan, Marketing, Approval, MHLW, Minnebro, Patients, Receives
12. Astellas and Amgen Astellas’ Evenity (romosozumab) Receives MHLW Approrval for Patients
with Osteoporosis at High Risk of Fracture in Japan
Published: 08 Jan, 2019 |Tags: Evenity, (romosozumab), Amgen, Astellas, Fracture,
High-Risk, Japan, MHLW, Osteoporosis, Patients, Receives
13. Novartis’s SEG101(crizanlizumab) receives FDA’s Breakthrough Therapy(BT) designation for
sickle cell disease
Published: 08 Jan, 2019 |Tags: Novartis, (crizanlizumab), Breakthrough Therapy
Designation, FDA, Receives, SEG101, Sickle Cell Disease, (BT)
14. 3SBio Signs a License Agreement with Samsung Bioepis for its Biosimilars
Published: 08 Jan, 2019 |Tags: 3SBio, Agreement, Biosimilars, License, Samsung Bioepis,
Signs
15. Sandoz and Pear Therapeutics Launches reSET-O Mobile App for Opioid Use Disorder (OUD)
Patients
Published: 08 Jan, 2019 |Tags: (OUD), Launches, Mobile App, Opioid Use Disorde, Pear
Therapeutics, reSET-O, Sandoz
16. Eli Lilly to Acquire Loxo Oncology for $8B
Published: 08 Jan, 2019 |Tags: Eli Lilly, Acquire, Loxo Oncology, LOXO-195, LOXO-292,
LOXO-305, P-I/II, Vitrakvi, Bayer
17. BlueBirdBio Signs an Exclusive License Agreement with Inhibrx for CAR T Cell Immunotherapies
Published: 07 Jan, 2019 |Tags: BlueBirdBio, CAR T, Cell Immunotherapies, Exclusive,
Inhibrx, License, Agreement, Signs
18. Bruin Biometrics Receives FDA’s Marketing Approval for SEM Scanner for Patients with
Pressure Ulcer
Published: 07 Jan, 2019 |Tags: Bruin Biometrics, Approval, FDA, Marketing, Pressure,
receives Scanner SEM Ulcer
19. Gilead Signs an Agreement with Yuhan Corporation to Develop Novel Therapy for Patients
with NASH (Nonalcoholic Steatohepatitis)
Published: 06 Jan, 2019 |Tags: Gilead, (Nonalcoholic Steatohepatitis), Agreement, Develop,
Nash, Republic of Korea, Signs, Therapies, Yuhan Corporation
